Evidence map›Paper›PMID 40797094›Full record

ArticleScientific reports2025

Genomic and phenotypic characterization of six multidrug-resistant Acinetobacter pittii isolates.

Nadya Rakovitsky, Mor Lurie-Weinberger, Alona Keren-Paz, Yehuda Carmeli

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Plasmid-borneOne health (Amsterdam, Netherlands) · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nadya RakovitskyNational Institute for Antibiotic Resistance and Infection Control, Ministry of Health, Tel Aviv, Israel. nadyarak@tlvmc.gov.il.
Mor Lurie-WeinbergerNational Institute for Antibiotic Resistance and Infection Control, Ministry of Health, Tel Aviv, Israel.
Alona Keren-PazNational Institute for Antibiotic Resistance and Infection Control, Ministry of Health, Tel Aviv, Israel.
Yehuda CarmeliNational Institute for Antibiotic Resistance and Infection Control, Ministry of Health, Tel Aviv, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Acinetobacter calcoaceticus-baumannii complex is a significant cause of nosocomial infections. While A. baumannii is the most common and clinically significant member globally, recent studies suggest that A. pittii is an emerging pathogen within the complex. Clinical A. pittii isolates have not been well characterized. In this study, we investigated the genomic and phenotypic characteristics of six clinical A. pittii isolates from five healthcare facilities. All isolates were resistant to ceftazidime and ertapenem, and one was resistant to imipenem and meropenem. Using whole genome sequencing and phylogenetic analysis, we found that isolates were not linked genetically, harbored OXA-type β-lactamase genes, and exhibited a wide array of virulence factors. Plasmids were identified in two isolates. Transfer of a plasmid carrying bla

Indexed as

AcinetobacterAcinetobacter InfectionsDrug Resistance, Multiple, BacterialAcinetobacter baumanniiAnimalsAnti-Bacterial Agentsbeta-LactamasesBiofilmsGenome, BacterialGenomicsHumansMicrobial Sensitivity TestsPhenotypePhylogenyPlasmidsVirulence FactorsAnti-Bacterial Agentsbeta-LactamasesVirulence FactorsAcinetobacter baumannii complexAcinetobacter pittiiCarbapenemaseCarbapenem resistancePlasmid transferVirulence factors

Identifiers

PMID40797094
PMCPMC12344141

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.